You are here

P&T® Journal contents for July 2004

Features

Meeting Highlights
The author summarizes the P&T Society’s Task Force Report in support of the initiatives undertaken by the Institute of Medicine to reduce medical errors. Opportunities for improvement, “practices of excellence,” and the Society’s perspective are outlined.
Joseph Eichenholz
Meeting Highlights
Presentations focused on improving the quality of health care and reducing the occurrence of medical errors. Also included were such topics as the role of the P&T Society, the Institute of Medicine’s agenda for health care quality and the P&T Society’s response, the findings of the Society’s Working Group, the impact of P&T committee decision strategies, the challenges of the economic environment, the Medicare Modernization Act of 2003, and formulary management.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
Recent advances in the treatment of musician’s dystonia, epilepsy, restless legs syndrome, Tourette syndrome, multiple sclerosis, Alzheimer’s disease, and migraine are presented.
Lawrence M. Prescott, PhD
Cover Story
Dr. Silver reviews the potential benefits of COX-1–sparing drugs. When compared with traditional NSAIDs, the judicious use of the COX-1–sparing agents can have improved effects on the GI tract and provide efficacious pain relief.
David S. Silver, MD

Departments

Editorial
David Nash, MD, MBA, presents the results of a survey detailing the public’s concern about medical errors and the quality of health care.
David Nash, MD, MBA
Medication Error
Matthew Grissinger, RPh, FASCP, explains the adverse consequences of unintended intrathecal therapy and the precautions to take in order to avoid near-fatal errors.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses the need for research on Alzheimer’s disease in today’s climate of restricted funding.
Stephen Barlas
Drug News

P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.

Drug Forecast
The authors review fosamprenavir (Lexiva™) for the treatment of HIV infection.
Nathaniel Eraikhuemen, PharmD, Natalie Perry, PharmD, Evans Branch III, PharmD, Daryl Norwood, PharmD, and Marlon Honeywell, PharmD